Stent Tune-Ups After Heart Procedures Boost Blood Flow, But Benefit Has Limits

When cardiologists open a blocked coronary artery with a stent, they increasingly check their work with a pressure wire that measures fractional flow reserve, or FFR — a ratio that reveals whether blood flow through the treated vessel is truly restored. Angiography alone can look convincing while significant pressure gradients persist, and studies over the past two decades have consistently shown that a disappointing FFR value after stenting predicts worse outcomes. A new systematic review and individual patient data meta-analysis, published in Clinical Research in Cardiology, now offers the most granular picture yet of what happens when operators actively try to fix those suboptimal results, and it arrives at a conclusion that is both encouraging and sobering.

Researchers led by Annemieke C. Ziedses des Plantes and Joost Daemen of Erasmus University Medical Center in Rotterdam screened 1,945 studies to find trials and cohort studies in which patients received a drug-eluting stent, then had FFR measured both before and after a deliberate optimization procedure — either inflating a balloon inside the existing stent, known as post-dilatation, or implanting an additional stent. Eleven studies met the criteria, and usable patient-level data were obtained from eight of them, yielding 314 patients in whom the complete before-and-after physiological picture could be reconstructed and analyzed with mixed-effects regression models that account for differences between studies.

The headline result is that optimization works, at least physiologically. Median FFR rose from 0.81 to 0.86, a statistically significant improvement, with the magnitude of the gain depending heavily on which technique was used. Post-dilatation alone added an average of 0.03 FFR points, while placing an additional stent produced an average increase of 0.08 points. The proportion of patients left with an ischemic FFR value of 0.80 or below dropped from 49 percent to 21 percent after the optimization procedure — a meaningful shift in a measurement where each hundredth of a point reflects improved perfusion across the treated segment.

Yet the number of patients who actually reached the conventional optimum of FFR at or above 0.90 was just 23.2 percent. In other words, fewer than one in four patients with a suboptimal result could be pushed into the ideal physiological range, even with a second intervention inside the vessel. This is a crucial nuance for a field that has been moving toward routine physiological verification of stent results: the tools available to correct a lingering pressure drop are limited, and the residual disease that produces a low post-stent FFR is often not something a balloon inflation can easily eliminate.

The multivariable analysis revealed which patients stood to gain the most. When the initial post-PCI FFR was low, adding a stent yielded substantially larger improvements than post-dilatation, but this advantage steadily shrank as the starting FFR rose — a statistical interaction that makes physiological sense, since a very low FFR usually signals residual disease beyond the stent edges or incomplete coverage of the lesion, problems that additional stenting directly addresses. Conversely, when the pressure wire shows an FFR close to 0.90 already, there is little residual obstruction left for another stent to relieve.

Location mattered as well. Lesions in the left anterior descending artery, the vessel that supplies the largest mass of heart muscle, showed smaller absolute FFR gains after optimization than lesions elsewhere, even after adjusting for the starting FFR value. The authors attribute this to the larger subtended myocardium and hydrostatic pressure effects along the long LAD, which depress FFR readings for reasons that no stent can correct. The finding supports a growing argument in the interventional cardiology literature that post-procedure FFR thresholds may need to be vessel-specific rather than uniform across the coronary tree.

Perhaps the most consequential negative result concerns clinical outcomes. With follow-up data available for 267 patients over a median of three years, the composite of target vessel revascularization or target vessel myocardial infarction occurred in about 11.7 percent of patients. Neither the final FFR achieved nor the size of the FFR improvement predicted who had events. Patients whose final FFR was at or above the median of 0.85 fared no better numerically than those below it — 8.9 percent versus 15.8 percent cumulative incidence, a difference that did not reach statistical significance — and the same held true when comparing large and small FFR gains.

The authors caution that this analysis was likely underpowered rather than proof that physiology-driven optimization is clinically useless. The patient group was selected precisely because of suboptimal starting values, creating a comparatively high-risk cohort in which the most dangerous anatomical problems may already have been corrected during the optimization itself. Only a minority of patients had FFR pullback data or intracoronary imaging available, preventing the researchers from mapping exactly where residual disease lurked. And the included studies used wildly different optimization protocols and FFR cut-offs, introducing heterogeneity that random-effects modeling can dampen but not eliminate.

Context from the broader literature sharpens the interpretation. Previous work has established that suboptimal post-stent FFR values appear in roughly 30 to 70 percent of angiographically successful procedures, and that they carry prognostic weight. The FFR REACT trial showed that guiding optimization with intravascular ultrasound in patients with post-PCI FFR below 0.90 reduced target vessel revascularization over three years, with a trend toward fewer target vessel failures. But this new meta-analysis found no advantage for imaging-guided protocols over operator discretion once the starting FFR was accounted for — a result the authors suggest may partly reflect the fact that imaging-guided procedures catch subtle problems earlier, leaving less room for improvement by the time a low FFR triggers optimization.

Two ongoing randomized trials, DEFINE GPS and INSIGHTFUL-FFR, are expected to clarify whether physiology-guided stent optimization can translate into fewer heart attacks and repeat procedures. Until those results arrive, this meta-analysis offers interventional cardiologists a practical algorithm: if the post-stent FFR is markedly low, especially outside the LAD and particularly when residual disease is suspected, additional stenting offers the best chance of physiological rescue; if the value hovers just below 0.90, the achievable gain is modest and the clinical payoff unproven. The pressure wire, it turns out, is excellent at telling operators when something is wrong — but far less reliable at predicting whether fixing it will change the patient’s story.

Subject of Research: Effectiveness of fractional flow reserve-guided optimization after coronary stenting

Article Title: Effectiveness and clinical impact of functional post-PCI optimization—a systematic review and individual patient-data meta-analysis

Article References: Ziedses des Plantes, A. C., Neleman, T., Hakeem, A., Uretsky, B. F., Agarwal, S. K., Miller, K., Collison, D., Oldroyd, K., Wijns, W., Leone, A. M., Burzotta, F., Trani, C., Galante, D., Leesar, M. A., Hoeks, S. E., Van Mieghem, N. M., & Daemen, J. (2026). Effectiveness and clinical impact of functional post-PCI optimization—a systematic review and individual patient-data meta-analysis. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03009-y

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03009-y

Keywords: fractional flow reserve, PCI optimization, percutaneous coronary intervention, drug-eluting stent, meta-analysis, cardiology, intravascular ultrasound, post-dilatation, LAD artery, target vessel revascularization, FFR-REACT, coronary physiology